New cancer drug targets KRAS mutations in first human trial
NCT ID NCT07300150
Summary
This is the first human study of an experimental drug called PT0511 for people with advanced solid tumors that have specific KRAS genetic changes. The main goals are to find safe doses and see how the body processes the drug, both alone and combined with another cancer medication for colorectal cancer. Researchers will enroll about 195 adults who have tried 1-4 other treatments to test safety and look for early signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber/Massachusetts General Hospital, Inc
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Email: •••••@•••••
-
New Experimental Therapeutics of San Antonio LLC
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
START - South Texas Accelerated Research Therapeutics, LLC
NOT_YET_RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
START Mountain Region
NOT_YET_RECRUITINGWest Valley City, Utah, 84119, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.